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Introduction: This investigator-initiated study explores the safety, 
maximum tolerated dose, clinical response, and pharmacokinetics 
of hydroxychloroquine (HCQ) with and without erlotinib in patients 
with advanced non–small-cell lung cancer.
Methods: Patients with prior clinical benefit from an epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitor were ran-
domized to HCQ or HCQ plus erlotinib in a 3 + 3 dose-escalation 
schema.
Results: Twenty-seven patients were treated, eight with HCQ (arm 
A) and 19 with HCQ plus erlotinib (arm B). EGFR mutations were 
detected in 74% of the patients and 85% had received two or more 
prior therapies. Arm A had no dose-limiting toxicities, but the 
maximum tolerated dose was not reached as this arm closed early 
to increase overall study accrual. In arm B, one patient each expe-
rienced grade 3 rash, nail changes, skin changes, nausea, dehydra-
tion, and neutropenia; one had grade 4 anemia; and one developed 
fatal pneumonitis, all considered unrelated to HCQ. There were no 
dose-limiting toxicities, therefore the highest tested dose for HCQ 
with erlotinib 150 mg was 1000 mg daily. One patient had a partial 
response to erlotinib/HCQ, for an overall response rate of 5% (95% 
confidence interval, 1–25). This patient had an EGFR mutation and 
remained on therapy for 20 months. Administration of HCQ did not 
alter the pharmacokinetics of erlotinib.
Conclusions: HCQ with or without erlotinib was safe and well toler-
ated. The recommended phase 2 dose of HCQ was 1000 mg when 
given in combination with erlotinib 150 mg.
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Non–small-cell lung cancer (NSCLC) is the most common cause of cancer mortality in the United States1 and che-
motherapy is only modestly effective. A subset of NSCLCs 
harbors a mutation in the epidermal growth factor receptor 
(EGFR) gene that imparts an oncogene-addicted biology, con-
ferring a distinct sensitivity to EGFR tyrosine kinase inhibi-
tors (TKIs).2–5 Acquired resistance arises after approximately 
1 year, so developing strategies to delay and treat resistance is 
of utmost clinical importance.1–8
Hydroxychloroquine (HCQ) and chloroquine (CQ) are 
immunomodulating agents widely prescribed for their anti-
malarial and antirheumatic effects. In addition, HCQ and CQ 
have been implicated as possible adjuncts to anticancer treat-
ment. This has been explored most extensively in a prospec-
tive study of patients with glioblastoma multiforme in which 
adding CQ to standard treatment (surgery, radiation therapy, 
and chemotherapy) improved survival compared with stan-
dard treatment alone.6
We recently described a subpopulation of cells present 
within several oncogene-addicted tumor-derived cell lines that 
display a reversible drug-tolerant phenotype,7 which can be 
spontaneously acquired and relinquished and allows them to 
survive within an otherwise drug-sensitive cancer. The drug-
tolerant phenotype is associated with an altered chromatin 
structure, rendering them sensitive to histone deacetylase 
(HDAC) inhibitors.7 Because HDAC inhibitors had been 
associated with poor efficacy and significant toxicity in clinical 
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studies available at the time we conceived of this project,8 we 
hypothesized that CQ and HCQ, which seem to alter chromatin 
structure similarly and are clinically well tolerated,9 could 
potentially be used to disrupt this reversible drug-tolerant state. 
Preclinical studies exploring this hypothesis are presented 
herein, and overall demonstrate that HCQ might have efficacy 
in EGFR-mutant NSCLC, either alone or in combination 
with erlotinib. Building from these results, we conducted a 
phase I trial investigating the safety and tolerability of HCQ 
with or without erlotinib in advanced NSCLC, with the long-
term objective of studying the combination in EGFR-mutant 
NSCLC.
PATIENTS AND METHODS
Laboratory Studies
We used the PC9 NSCLC model (exon 19 EGFR muta-
tion) to test the ability of CQ and HCQ to selectively promote 
cell death in the drug-tolerant subpopulation in vitro. We gen-
erated PC9-derived clones with reversible drug tolerance to 
gefitinib or erlotinib by continuous propagation in pharmaco-
logically relevant TKI concentrations, as previously described.7 
The resultant clones exhibit distinct morphology, have approxi-
mately 400-fold reduced EGFR TKI sensitivity compared 
with parental lines, and can be propagated indefinitely in TKI. 
Parental and TKI-tolerant clones were treated with variable 
concentrations of CQ and HCQ, and cell viability was assayed.7
Clinical Trial Design and Patients
To translate the laboratory findings to the clinic, we 
initiated a single-center, open-label, dose-escalation phase I 
trial of HCQ with or without erlotinib in advanced NSCLC 
patients who previously responded to an EGFR TKI. The pri-
mary outcome was safety and to determine the maximum tol-
erated dose (MTD) of HCQ. Secondary objectives included 
response and pharmacokinetics (PK). The study was approved 
and monitored by our Institutional Review Board and all 
patients provided written informed consent. Funding for this 
investigator-initiated study was provided by Genentech and 
the Dana-Farber/Harvard Cancer Center SPORE in Lung 
Cancer, National Cancer Institute P50 CA090578 (JS), and 
the trial was listed on clinicaltrials.gov before patient enroll-
ment (National Clinical Trial #NCT01026844).
Eligible patients had advanced NSCLC (stage IIIB/ 
pleural effusion or IV by American Joint Committee on 
Cancer 6th edition)10 with an Eastern Cooperative Oncology 
Group performance status of 0 to 2.11 Prior clinical benefit 
from EGFR TKI, defined as 12 weeks or more of erlotinib 
or gefitinib was required. There was no restriction on prior 
therapies and central nervous system disease was allowed 
if definitively treated and clinically stable. All patients had 
measurable disease by Response Evaluation Criteria In Solid 
Tumors 1.0 (RECIST 1.0),12 adequate end organ function, and 
an eye exam that excluded retinal disease given the potential 
for HCQ-induced retinopathy.13
The study was initially designed as a two-armed ran-
domized phase I trial in which each arm independently 
underwent HCQ dose escalation starting at 400 mg daily and 
increasing by 200 mg increments to a maximum planned dose 
of 1000 mg. Patients were randomly assigned to HCQ mono-
therapy (arm A) or HCQ plus erlotinib at 150 mg daily (arm 
B). Arm B patients received a 1-week erlotinib run-in prior to 
HCQ initiation for PK purposes. Treatment was divided into 
continuous 28-day cycles and proceeded until disease pro-
gression or unacceptable toxicity. All subjects in a given dose 
cohort were observed for one complete cycle before accrual to 
the next dose level began.
Adverse events (AEs) were assessed using the National 
Cancer Institute Common Toxicity Criteria (CTC) version 
3.0.14 Dose-limiting toxicities (DLTs) were defined as CTC of 
grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or 
higher hematologic, skin, CNS, neuropathic, cardiac, respira-
tory, gastrointestinal, or renal AEs in the first cycle considered 
at least possibly related to HCQ. If a DLT was observed, an 
additional three patients were enrolled at that dose level. The 
MTD for HCQ in each arm would be defined as one dose level 
below that at which two or more of 6 patients experienced a 
DLT, or if no DLTs were observed, the highest tested dose. 
Upon reaching the MTD or highest tested dose, an expansion 
cohort of up to 12 patients was planned in each arm.
In October 2008, after enrollment of 18 patients (8 on 
arm A and 10 on arm B), the study was amended to limit 
enrollment to arm B only (HCQ plus erlotinib) given the 
increasing preclinical evidence supporting a role for combina-
tion therapy (but not HCQ monotherapy) and to help increase 
overall patient accrual.
Trial Assessments and Pharmacokinetic Studies
Patients were assessed every 4 weeks through cycle 6, 
and every 8 weeks thereafter. Dilated eye exams occurred at 
baseline and every 3 months; radiographic imaging for effi-
cacy was performed every 8 weeks and determination of best 
response to therapy was made using RECIST 1.0.12
PK samples were obtained weekly during cycle 1 and 
monthly thereafter from all patients to monitor the steady-state 
minimum concentration (C
min
ss) of HCQ. For patients in arm 
B, sampling over two 24-hour intervals on day 7 of erlotinib 
monotherapy and again on day 7 of combination erlotinib and 
HCQ was performed to define the plasma concentration time 
profile of erlotinib. HCQ C
min
ss was determined by liquid chro-
matography/mass spectrometry. Erlotinib PK was assessed by 
liquid chromatography-tandem mass spectrometry, as previ-
ously reported but with minor modifications.15,16 For addi-
tional details see Supplemental Digital Content 1 (http://links.
lww.com/JTO/A331).
Statistical Considerations
All patients were included in all analyses. Safety data 
was analyzed using summary statistics. Response rate (RR) 
was calculated separately for each arm. Progression-free sur-
vival (PFS) was the time from enrollment until progression or 
death and overall survival (OS), from enrollment until death. 
Survival analyses were performed using the Kaplan–Meier 
method.
The C
min
ss of HCQ was calculated for each patient as the 
geometric mean of all acceptable determinations. Individual 
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FIGURE 1.  Disruption of drug resistance by chloroquine or hydroxychloroquine. A, Photomicrographs illustrating the morphology 
of untreated PC9 non-small cell lung cancer cells and three representative clones that had been selected for resistance either to 
gefitinib (GR3) or erlotinib (ER3 and ER4) by continuous culture in 1 µM drug for several weeks. B, Viability of parental PC9 cells 
and several GR or ER PC9-derived clones following 72 hr treatment with 10 µM CQ, as measured using SYTO60 nuclear staining. 
C, Comparison of the effects of CQ and HCQ on the viability of representative tested resistant clones using the assay described 
in B. D, Upper panels: Representative plates of cells stained with SYTO60 after drug treatment in the presence or absence of 
HCQ for the indicated number of days. Included are PC9 cells treated with ERL or CISPLAT, the HER2-amplified breast cancer 
cell line SKBR3, treated with the HER2 kinase inhibitor LAPAT, and the BRAF-mutant melanoma cell line M14 treated with the 
RAF kinase inhibitor AZ628. Lower panels: Graphs depicting the quantitative analysis of drug-resistant colonies detected, as 
averaged from three independent plates, with error bars representing the standard deviation. GR, gefitinib; ER, erlotinib resis-
tant; CQ, chloroquine; HCQ, hydroxychloroquine; CISPLAT, cisplatin; LAPAT, lapatinib; ERL, erlotinib.
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erlotinib plasma concentration time curves were analyzed 
by standard noncompartmental methods using WinNonlin 
Professional version 5.0 software (Pharsight Corp., Cary, 
NC). Area under the plasma concentration time curve (AUC
24
) 
for erlotinib was estimated using the log-linear trapezoidal 
algorithm. Apparent oral clearance was calculated as the dose 
divided by AUC
24
. The t test (two-sided) was used to compare 
PK parameters after logarithmic transformation.
RESULTS
Laboratory Studies
PC9-derived clones with reversible tolerance to gefitinib 
(gefitinib resistant [GR]) or erlotinib (erlotinib resistant [ER]) 
were made (Fig. 1A). CQ at 10 µM did not affect viability 
or growth of the parental PC9 cells, but was associated with 
dramatic reduction in cell viability in both gefitinib resistant 
and erlotinib resistant, with 70% to 98% reduced cell sur-
vival after 72 hours of CQ treatment (Fig. 1B). HCQ at 10 µM 
led to similar findings (Fig. 1C). To examine whether HCQ 
could affect the initial emergence of the drug-tolerant clones, 
cotreatment of parental PC9 cells with erlotinib and HCQ was 
performed. We observed an approximate 90% reduction in the 
number of TKI-tolerant clones detected at 33 days, under con-
ditions in which HCQ monotherapy did not detectably affect 
growth or survival (Fig. 1D).
We evaluated three additional treatment settings to 
address the potentially broader ability of HCQ to disrupt drug-
tolerant clone formation. Coadministration of HCQ substan-
tially suppressed formation of drug-tolerant clones in PC9 cells 
treated with cisplatin, human epidermal growth factor receptor 
2 (HER2)-amplified SKBR3 breast cancer cells treated with 
the HER2 TKI lapatinib, and BRAF-mutant melanoma cells 
treated with the BRAF TKI AZ628 (Fig. 1D).
Patients
Twenty-seven patients were enrolled between August 
2007 and May 2010; eight to arm A, 12 to the dose-escalation 
portion of arm B, and seven to the arm B MTD expansion. 
There were 14 women and 13 men with a median age of 66 
years (range, 27–76; Table 1). All tumors were adenocarci-
noma and 20 (74%) were EGFR mutation positive (5 patients 
were EGFR wild type, 2 had unknown EGFR status). Patients 
were heavily pretreated, with 10 (37%) having two prior treat-
ments and 13 (48%) having three or more.
Safety and Toxicity
Treatment was generally well tolerated, with most AEs 
categorized as grades 1 and 2 (Table 2). The most commonly 
observed treatment-related AEs were rash (37%), nausea 
(33%), diarrhea (33%), and fatigue (30%). Vomiting, dys-
pepsia, anorexia, and dry skin occurred in less than 20% of 
patients. AEs of grade 3 or higher were uncommon and were 
all considered unrelated to HCQ. One patient each experi-
enced grade 3 rash, nail changes, skin changes, nausea, dehy-
dration, and neutropenia; one developed grade 4 anemia; and 
one had fatal pneumonitis about 1 month into erlotinib plus 
HCQ 400 mg daily (note this patient had previously received 
10 months of gefitinib and 2 months of dacomitinib without 
pneumonitis). Toxicity of grade 3 or higher did not seem to 
be dose dependent (4 at HCQ 400 mg, 1 at HCQ 600 mg and 
3 at HCQ 1000 mg, all with concurrent erlotinib). Overall, the 
majority of treatment-related AEs were observed in arm B.
No DLTs were observed in either arm. Therefore, the 
MTD for HCQ when given in combination with erlotinib 
150 mg daily is 1000 mg, which was the highest dose tested. 
The MTD for HCQ alone could not be determined because 
enrollment to that arm was closed early.
Efficacy
Twenty-three patients (7 on arm A, 16 on arm B) under-
went radiographic evaluation (Fig. 2). One patient electively 
withdrew from the study in cycle 1 and three patients pro-
gressed clinically before restaging. All patients on arm A 
had progressive disease as their best response to therapy 
(RR 0%; 95% CI, 0–34). In arm B, one patient of 19 had a 
TABLE 1. Patient Characteristics
Variable
HCQ Alone 
(N = 8)
HCQ + Erlotinib 
(N = 19)
Age in yrs, median (range) 61 (48–76) 65 (27–73)
Sex, n (%)
 Female 5 (63) 9 (47)
 Male 3 (38) 10 (53)
Race, n (%)
 White 7 (88) 16 (84)
 Asian 1 (13) 2 (11)
 Other — 1 (5)
Baseline PS, n (%)
 0 3 (38) 9 (47)
 1 5 (63) 8 (42)
 2 — 2 (11)
Smoking status, n (%)
 Never 5 (63) 10 (53)
 Former 1 (13) 9 (47)
 Current 2 (25) —
Histology, n (%)
 Adenocarcinoma 8 (100) 19 (100)
EGFR mutation status, n (%)
 Mutant: Exon 19 del 4 (50) 9 (47)
 Mutant: L858R 1 (13) 2 (11)
 Mutant: other 1 (13) 3 (16)
 Wild type 2 (25) 3 (16)
 Unknown — 2 (11)
Number of prior regimens, n (%)
 1 1 (13) 3 (16)
 2 4 (50) 6 (32)
  ≥ 3 3 (38) 10 (53)
Last prior therapy, n (%)
 EGFR TKI 6 (75) 10 (53)
 Other 3 (38) 9 (47)
HCQ, hydroxychloroquine; EGFR, epidermal growth factor receptor; TKI, tyrosine 
kinase inhibitors; PS, performance status.
1606 Copyright © 2012 by the International Association for the Study of Lung Cancer
Goldberg et al. Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012
partial response (PR) and four had confirmed stable disease 
(SD), for an overall response rate of 5% (95% CI, 1–25) and a 
disease-control rate (PR + SD) of 26% (95% CI, 12–49). The 
patient who had a PR received HCQ 600 mg plus erlotinib and 
remained on therapy for 20 months. Her tumor had an exon 
19 deletion EGFR mutation and there was an interval of 2 
years since prior EGFR TKI. All four patients who attained 
SD remained on therapy for 16 weeks or more, including 
one EGFR-mutant, two EGFR wild type, and one EGFR 
unknown. All four had three or more prior regimens; only one 
had received erlotinib as the immediate prior regimen, and she 
achieved SD for 16 weeks with HCQ 400 mg plus erlotinib.
Overall median follow-up time was 9.1 months. The 
median PFS was 1.8 months (95% CI 0.7, 1.8) in arm A and 2 
months (95% CI 1.5, 3.8) in arm B. Median OS was 9 months 
(95% CI 1.4, 38.5) in arm A and 10.6 months (95% CI 3.6, 14.1) 
in arm B.
Pharmacokinetics
Data were available to estimate the C
min
ss of HCQ in 
whole blood and plasma for eight patients in arm A and 13 
patients in arm B. As shown in Figure 3, the average C
min
ss of 
HCQ in whole blood and plasma increased progressively as 
the daily HCQ dose was escalated from 400 mg/day to 800 mg/
day in both study arms. Accordingly, dose-normalized C
min
ss 
values in patients treated with 400 mg/day to 800 mg of HCQ 
were used to assess the effect of erlotinib on the steady-state 
PK of HCQ. The mean dose-normalized C
min
ss of HCQ was 
lower when given with erlotinib than as monotherapy, in both 
whole blood (5.93 ± 2.51 µM/g, n = 9 for combination and 
9.40 ± 5.85 µM/g, n = 8 for monotherapy; p = 0.12) and plasma 
(1.00 ± 0.40 µM/g, n = 9 for combination and 1.64 ± 0.61 µM/g, 
n = 8 for monotherapy; p = 0.015). The blood-to-plasma ratio 
for the C
min
ss of HCQ was similar (p = 0.33) in the combination 
(6.14 ± 1.54) and in HCQ monotherapy (5.42 ± 1.55).
Steady-state erlotinib plasma concentration time pro-
files were obtained in 10 patients during two 24-hour dosing 
intervals—once after the 7-day erlotinib run-in and 1 week 
into combination therapy with HCQ 400 mg/day to 800 mg/
day, Table 3. There were no significant differences between 
any measured parameters, suggesting that concurrent 
administration of HCQ does not affect the plasma PK of 
erlotinib in this patient population.
DISCUSSION
We studied PC9 models of acquired resistance to EGFR 
inhibitors and identified two experimental conditions in which 
HCQ had cytotoxic activity in the context of drug tolerance in 
EGFR-mutant NSCLC. Cells with acquired resistance were 
effectively killed by HCQ at concentrations that had not affected 
the parental TKI-sensitive cells. In addition, we observed that 
initial treatment with HCQ plus EGFR TKI could prevent the 
TABLE 2.  Treatment-Related Toxicities That Occurred in At Least 10% of Subjects or Were Serious
Event
HCQ Alone, n = 8
n (%)
HCQ + Erlotinib, n = 19
n (%) Total, N = 27
All Grades
n (%)Gr 1 Gr 2 Gr 1 Gr 2 Gr 3 Gr 4 Gr 5
Rash — — 8 (42) 1 (5) 1 (5) — — 10 (37)
Diarrhea — — 5 (26) 4 (21) — — — 9 (33)
Nausea 2 (25) 1 (13) 2 (11) 3 (16) 1 (5) — — 9 (33)
Fatigue 1 (13) — 4 (21) 3 (16) — — — 8 (30)
Vomiting 3 (38) — 2 (11) — — — — 5 (19)
Dyspepsia — — 4 (21) 1 (5) — — — 5 (19)
Anorexia — — 3 (16) 2 (11) — — — 5 (19)
Dry skin — — 3 (16) 2 (11) — — — 5 (19)
Nail changes — — 1 (5) 1 (5) 1 (5) — — 3 (11)
Skin, other — — — 2 (11) 1 (5) — — 3 (11)
Ocular, other — — 2 (11) 1 (5) — — — 3 (11)
Anemia — 1 (13) — 1 (5) — 1 (5) — 3 (11)
Neutropenia — — — — 1 (5) — — 1 (4)
Pneumonitis — — — — — — 1 (5) 1 (4)
Dehydration — — — — 1 (5) — — 1 (4)
HCQ, hydroxychloroquine; Gr, grade.
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FIGURE 2. Individual response to therapy. Bars indicate the 
individual patient best response to treatment expressed as 
a percent change of tumor burden compared with baseline 
for HCQ alone (white) and HCQ plus erlotinib (black). HCQ, 
hydroxychloroquine.
1607Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012 Erlotinib & Hydroxychloroquine in Advanced NSCLC
development of drug-tolerant clones. We therefore designed 
and performed a phase I clinical study of HCQ with or without 
erlotinib to assess safety, as a foundation for a future study to 
evaluate the suppression of acquired TKI-resistance. We found 
that HCQ was safe and well tolerated in NSCLC patients previ-
ously treated with EGFR TKIs. The MTD of HCQ when given 
with 150 mg of erlotinib daily was the highest tested dose, 
1000 mg daily. Treatment-related side effects were mild (pre-
dominantly of grades 1–2) and were consistent with the known 
toxicity profile of erlotinib, including rash, fatigue, diarrhea, 
and nausea.17 There were few AEs of grade 3 to 5, and no DLTs.
We did not observe robust clinical activity in this heav-
ily pretreated cohort, with the notable exception of an EGFR-
mutant patient with a durable response to erlotinib plus HCQ. 
The etiology of her initial response may have been retreatment 
effect, which is a well-documented phenomenon in a subset 
of EGFR mutants.18,19 However, the 20-month duration of her 
response was longer than we have anecdotally experienced 
with erlotinib retreatment.
To our knowledge, this is the first clinical report assessing 
HCQ in combination with erlotinib, though there have been sev-
eral clinical trials examining CQ or HCQ in cancer patients.6,20 
One relevant study was a small prospective randomized trial of 
glioblastoma multiforme patients in whom CQ was adminis-
tered with standard surgery, radiation, and temozolomide che-
motherapy. Those treated with CQ had a significantly longer 
OS than the controls, with an increase in the median survival 
from 11 to 24 months.6 Another single-arm study of patients 
with EGFR-mutated, TKI-naive NSCLC treated with HCQ plus 
gefitinib is ongoing. Interim analysis of 13 patients on this study 
yielded an 11.5 month median PFS, suggesting that the combi-
nation might delay acquired resistance compared with historic 
gefitinib controls (Chin TM, submitted for publication). Other 
ongoing studies are examining the effect of HCQ plus chemo-
therapy in breast, colorectal, pancreas and NSCLC.21
There are several mechanisms by which HCQ could 
potentiate the effects of erlotinib, specifically in TKI-resistant 
tumors. This article describes preclinical evidence that HCQ 
may disrupt the drug-tolerant state that occurs after lethal drug 
exposure, possibly through effects on chromatin structure 
similar to those induced by HDAC inhibitors.7 Interestingly, 
HCQ also seems to be effective at delaying the development 
of the drug-tolerant state in NSCLC cells treated with erlo-
tinib or cisplatin, breast cancer cells treated with a HER2 TKI, 
and melanoma cells treated with a BRAF TKI, suggesting that 
HCQ may be a beneficial adjunct to therapy in a broad range 
of clinical applications.
CQ and HCQ have also been postulated to directly 
inhibit autophagy. Under conditions of cellular stress such 
as TKI-mediated inhibition of critical signaling pathways, 
autophagy is activated to clear damaged cellular debris and 
allow for cell survival.22 Preclinical studies have shown that 
blocking autophagy along with a TKI seems to enhance cell 
death.23 In pancreatic cancer cell lines and mouse xenograft 
models with constitutive autophagic activation, the addition of 
CQ resulted in autophagy inhibition with decreased prolifera-
tion of cells and marked tumor regression.24 In addition, the 
use of CQ in a mouse xenograft model of pancreatic cancer 
caused marked tumor regression and prolonged survival with 
evidence of autophagy inhibition and elevated DNA damage.24
A final mechanism by which CQ and HCQ may enhance 
erlotinib-mediated cell killing is through lysosomal pathway 
FIGURE 3. Pharmacokinetic Assays. Cmin
ss is measured 
in (A) whole blood and (B) plasma. Data points represent 
Cmin
ss values for individual patients who received HCQ alone 
(open markers) or in combination with erlotinib (closed 
markers). The solid bars depict mean values of the Cmin
ss for 
the group of patients evaluated at each dose level. HCQ, 
hydroxychloroquine.
TABLE 3. Comparison of Erlotinib Steady-State 
Pharmacokinetic Parameters When Given Alone and in 
Combination with Daily Hydroxychloroquine
Concurrent 
Hydroxychloroquine Difference
Parameter − + (%) pa
C
0
 (µM) 2.52 ± 1.92 2.13 ± 1.51 −15.2 0.17
C
max
 (µM) 5.48 ± 2.09 4.71 ± 4.95 −14.0 0.13
AUC
24
 (µM·h) 88.7 ± 43.9 76.2 ± 29.9 −14.1 0.19
CL/F (l/hr) 4.3 ± 2.1 5.0 ± 2.0 16.5 0.190
aPaired two-sample t test for means of log-transformed data.
C
0
, drug concentration in plasma measured immediately before dosing; C
max
, 
maximum concentration of drug in plasma; AUC
24
, area under the plasma concentration 
time curve during the 24-hr interval between two doses; CL/F apparent oral clearance.
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disruption. Cell line and human tumor models show that the 
CQ-mediated impairment of maturation from endosome to 
lysosome results in decreased intralysosomal degradation of 
phosphorylated EGFR, which in turn causes overexpression 
of activated EGFR. This seems to make TKI-resistant cells 
more dependent on the EGFR signaling pathway, thereby 
increasing their sensitivity to EGFR TKI (Chin TM, submit-
ted for publication).
PK analyses from our study showed that administration of 
HCQ at doses of 400 mg/day to 800 mg/day for 7 days did not 
result in significant changes in the mean value of any PK variable 
for erlotinib. The mean trough blood and plasma concentrations 
of HCQ in arm A patients were in good agreement with prior 
studies.25,26 Concurrent erlotinib resulted in a decrease in trough 
concentration of HCQ, consistent with enhanced first-pass HCQ 
metabolism from erlotinib-mediated CYP3A4 induction.27–29
The study must be interpreted within the context of 
its limitations. This was a phase I study designed to evaluate 
safety. The low response to treatment in the study cohort may 
have been influenced by potentially ineffective doses of HCQ 
in the early cohorts, or by a heavily pretreated patient popula-
tion. Furthermore, the laboratory work leading to the phase I 
trial concept focused on EGFR-mutant models whereas the 
inclusion criteria for the study dictated only prior receipt of 
12 weeks or more of TKI, thus enriching for EGFR mutants 
but not excluding wild-type patients. Mandating EGFR muta-
tions may ultimately prove a better strategy for studying the 
effect of HCQ, and we have initiated a randomized phase II 
study (NCT00977470) in TKI-naive EGFR mutants. Patients 
are assigned to erlotinib alone or erlotinib plus HCQ, under 
the hypothesis that the HCQ arm will have delayed emergence 
of drug resistance and prolonged PFS.
In conclusion, laboratory studies of PC9-derived EGFR-
TKI–tolerant cells suggested sensitivity to HCQ, and that 
cotreatment with HCQ and EGFR TKI could delay the emer-
gence of the drug-tolerant state. We have found in this phase 
I study that the combination of HCQ 1000 mg and erlotonib 
150 mg daily is safe and well tolerated, with a suggestion of 
clinical benefit in a subset of patients with advanced NSCLC 
who had previously benefitted from an EGFR TKI. A phase 
II trial assessing the added benefit of HCQ with erlotinib in 
EGFR-mutant NSCLC is currently underway.
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